BioprintingContestMedical Research

Aspect Biosystems launches bioprinting grant program

Two research labs will be awarded free access to an RX1 unit for six months

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Canadian bioprinter developer Aspect Biosystems has launched a new grant program aimed at promoting the use of bioprinting in research and making it more accessible. The program, which is now accepting applications, will provide an RX1 bioprinter to two research labs at no cost for a six-month period.

The eligibility criteria for the bioprinting program is fairly straightforward: applications must be pursuing research at a university or non-profit research institute and their projects must not include clinical trials or human use. Beyond that, Aspect Biosystems is looking for research projects with scientific merit, good feasibility and a “cool factor”.

Those interested in applying for the bioprinter grant program must submit their application by October 16, 2020. The two research labs selected by the bioprinting firm will be provided with support and training from the Aspect Biosystems team as well as free access to the company’s RX1 bioprinter for six months.

Aspect Biosystems grant program

The RX1 system is a microfluidic bioprinter capable of producing realistic physiological structures like human tissues for medical research, regenerative medicine and drug discovery applications. The sophisticated bioprinting platform is today in use around the world by researchers pursuing innovative projects in the neural and cardiac fields, among others. Aspect Biosystems also leverages its technology to conduct research in-house, focused on the development of tissue therapeutics for orthopedic and metabolic disorders.

When we spoke to Aspect Biosystems earlier this year as part of our Medical AM Focus 2020, the company revealed that one of the most interesting regenerative medicine applications it is exploring in its work is the production of pancreatic tissue, which could be used to treat diabetes patients.

“A patient with type 1 diabetes has a pancreas that does not perform its intended functions of secreting insulin and regulating blood sugar levels,” the company told us at the time. “Therefore, we are not aiming to create a replacement pancreas, but rather an implantable tissue therapeutic that would restore the the intended functions of the organ.

“Microfluidic-based 3D bioprinting enables the creation of well-defined microstructures, thus allowing us to print a tissue structure with specific features such as immune-protection, vascularization, or production of hormones like insulin. In the case of pancreatic tissue, microfluidics gives us the ability to print a multi-layered structure with a core of insulin-producing pancreatic islet cells (stem cell-derived beta-like cells) surrounded by an immuno-protective layer.”

Research 2022
Polymer AM Market Opportunities and Trends

741 unique polymer AM companies individually surveyed and studied. Core polymer AM market generated $4.6 billion...

Tess Boissonneault

Tess Boissonneault is a Montreal-based content writer and editor with five years of experience covering the additive manufacturing world. She has a particular interest in amplifying the voices of women working within the industry and is an avid follower of the ever-evolving AM sector. Tess holds a master's degree in Media Studies from the University of Amsterdam.

Related Articles

Back to top button

We use cookies to give you the best online experience and for ads personalisation. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services



Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*